Physician profile
Sander J Paul
NPI 1447331764
$12,575.73
in general payments reported to CMS, 2019-2025
57 companies · $2,274 in 2025
The $2,274 reported for 2025 was more than what 79% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $955 · 2021: $1,598 · 2022: $2,250 · 2023: $2,346 · 2024: $2,717 · 2025: $2,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,333 · Education: $4.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,333.48 |
| Education | $4.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,559.78 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,542.42 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,014.35 | 2019-2025 | Tepezza, Evenity, Prolia |
| Dexcom, INC. | $1,005.70 | 2019-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $709.92 | 2020-2025 | Jardiance, Tradjenta, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $575.66 | 2022-2025 | |
| Mannkind Corporation | $455.19 | 2019-2025 | Afrezza |
| Corcept Therapeutics | $447.13 | 2020-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $414.87 | 2019-2025 | |
| Medtronic, INC. | $387.34 | 2021-2025 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $336.22 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Abbvie INC. | $323.68 | 2021-2025 | |
| Radius Health, INC. | $289.38 | 2020-2025 | Tymlos |
| Abbott Laboratories | $271.28 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Insulet Corporation | $252.89 | 2019-2025 | Omnipod |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $205.89 | 2020-2023 | Tepezza |
| Astellas Pharma US INC | $193.89 | 2023-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $182.14 | 2019-2022 | |
| Alvogen INC | $169.47 | 2022-2025 | Teriparatide |
| Amneal Pharmaceuticals LLC | $169.28 | 2020-2025 | Unithroid |
| Neurocrine Biosciences, INC. | $157.82 | 2024-2025 | |
| Ascendis Pharma Endocrinology INC | $123.22 | 2025 | Yorvipath |
| Becton, Dickinson and Company | $117.18 | 2020-2022 | |
| Lifescan, INC. | $110.04 | 2019-2023 | |
| Ibsa Pharma INC. | $105.94 | 2020-2025 | Tirosint, Licart, Tirosint |
| Recordati_rare_diseases_inc. | $103.38 | 2022-2025 | Isturisa, Signifor Lar |
| Ascensia Diabetes Care US INC. | $101.64 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $81.60 | 2020-2025 | Strensiq |
| Ipsen Biopharmaceuticals, INC | $80.65 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $78.81 | 2019-2021 | |
| Tandem Diabetes Care, INC. | $75.75 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic Minimed, INC. | $75.48 | 2019-2020 | |
| Antares Pharma, INC. | $70.21 | 2020-2023 | Nocdurna, Xyosted, Tlando |
| Esperion Therapeutics, INC. | $65.87 | 2021-2024 | Nexletol |
| Tolmar, INC. | $59.37 | 2024 | |
| Amphastar Pharmaceuticals, INC. | $57.06 | 2024-2025 | |
| Embecta Corp. | $55.23 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Averitas Pharma INC. | $49.34 | 2023-2025 | Qutenza |
| Halozyme INC | $46.36 | 2023 | |
| Madrigal Pharmaceuticals | $41.78 | 2025 | Rezdiffra |
| Ultragenyx Pharmaceutical INC. | $40.94 | 2021-2022 | |
| Chiesi USA, INC. | $39.06 | 2025 | Juxtapid, Mycapssa |
| Clarus Therapeutics INC. | $36.38 | 2021 | |
| Janssen Pharmaceuticals, INC | $33.04 | 2019 | |
| Pfizer INC. | $32.70 | 2023-2024 | |
| Verity Pharmaceuticals INC. | $31.91 | 2024-2025 | Tlando |
| Amryt Pharma Holdings LTD | $31.88 | 2023 | Mycapssa |
| Acella Pharmaceuticals, LLC | $27.93 | 2024-2025 | NP Thyroid 60 |
| Cequr Corporation | $26.15 | 2021-2024 | Cequr Simplicity |
| Beta Bionics, INC. | $19.37 | 2023-2024 | Ilet Bionic Pancreas |
| Eusa Pharma (US) LLC | $18.09 | 2022 | |
| Zealand Pharma US, INC. | $17.67 | 2021 | |
| Acerus Pharmaceuticals Corporation | $16.42 | 2020 | |
| Theracosbio, LLC | $15.07 | 2024 | Brenzavvy |
| Glaxosmithkline, LLC. | $14.17 | 2025 | Shingrix |
| Grt US Holding, INC. | $11.74 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,251,754.94 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sander Paul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.